

Annual Workshop on Breast Cancer
Organized by Regional Network for Breast Cancer Research / OSBREAC
Kongsvold Fjellstue, Dovre, September 12-14, 2016
<http://www.kongsvold.no/>

Monday September 12th

13.30 - 17.00 Steering committee meeting starting with a light meal

20.00 Dinner

Tuesday September 13th

07.30 - 08.30 Breakfast

8.30 - 9.30 Keynote lecture:
“ From genotype to molecular phenotype by proteomics” Janne Lethiö, Karolinska Institute, Sweden
Chair: Anne-Lise Børresen-Dale

Session I: Data integration: genomics, epigenomics, proteomics, metabolomics
Chair: Hege Russnes

09.30 - 09.50 “CARMA; Is the genomic architecture in tumors of clinical importance?” Hege G. Russnes, Department of Cancer Genetics, OUS

09.50 - 10.10 “Integrated Epigenetics” Thomas Fleisher, Department of Cancer Genetics, OUS

10.10 - 10.40 Coffee

10.40 - 11.00 “Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes” Tonje Haukaas, NTNU

11.00 - 11.20 “Integrative clustering reveals a novel split in the luminal A subtype of breast cancer”, Kristine Sahlberg, Department of Research, Vestre Viken / Oslo University Hospital

11.20 - 11.40 “Proteomics by use of reverse phase protein arrays (RPPA) - examples from the NeoAva-study”, Mads Haugland, Department of Tumor Biology, OUS



11.40 - 12.00 “Highlights from abstracts”, Vessela Kristensen, Department of Cancer Genetics, Oslo University Hospital / Akershus University Hospital

12.00 - 15.00 Hiking and study of muskous anatomy - lunch in the mountains

Session II: Update and highlights from various sub-studies in the consortium

Maximum 5 min each

Chair: Bjørn Naume

- 15.00 - 16.15 IBCT: Olav Engebråten, Oslo University Hospital
Neo-BCT: Helle Skjerven, Vestre Viken
NeoAva: Olav Engebråten, Oslo University Hospital
OSL2: Kristine Sahlberg, Oslo University Hospital/Vestre Viken
ALICE: Bjørn Naume, Oslo University Hospital
Radiologigransking: Kristine Sahlberg, Vestre Viken
- 16.15-16.40 Coffee
- 16.40-18.00 Update cont.
- Cancer-ID: Bjørn Naume, Oslo University Hospital
Petremac: Randi Mathiesen and Emiel Janssen, Ahus/Stavanger University Hospital
Neoletexe: Jürgen Geisler, Akershus University Hospital
Immune therapy: Bjørnar Gilje, Stavanger University Hospital



Wednesday September 14th

- 07.30 - 08.30 Breakfast
- 08.30 - 9.30 Keynote lecture:
“Mass spectrometry driven systems biology approaches to understand human cell biochemistry”, Óttar Rolfsson, Center for Systems Biology, University of Island
Chair: Gunhild Mælandsmo

Session III: Highlights from the different partners:

Chair: Therese Sørli

- 9.30 - 10.00 Department of Tumor Biology, Oslo University Hospital:
“Extrinsic and intrinsic regulation of breast epithelial plasticity”, Bylgja Hilmarisdottir,
“OGT and O-GlcNAcylation in breast cancer”, Anna Barskovskaya
- 10.00 - 10.20 Coffee / checking out
- 10.20 - 11.00 MR Cancer group, The Norwegian University of Science and Technology:
“Metabolomics in the EBBA2 -study”, Guro F. Giskeødegård
“Glutaminase inhibition in PDX-models of breast cancer” Maria Tunset Grinde

“FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis”, Marit Valla, Pathology.

11.00 - 11.30 Akershus University Hospital:

“Non invasive assays for interleukins/ cytokines in serum from patients from the MicMa and the NeoAva studies”, Shakila Jabeen.

11.30 - 12.00 Stavanger University Hospital:

“METABOLITE-GUIDED TAMOXIFEN THERAPY ON PREDICTION OF OUTCOME IN BREAST CANCER PATIENTS WITH A LONG-TERM FOLLOW-UP: Preliminary results from a research collaboration between the Oslo-1 study and PBCB”, Thomas Helland, Endocrine Surgery.

“Circulating tumor cells detected by immunomagnetic depletion and quantitative RT-PCR in early breast cancer patients: preliminary results from the PBCB study”, Oddmund Nordgård, Oncology.

“The prognostic impact of cell cycling kinetics of proliferating cells and centrosome amplification in triple negative breast cancer”, Emiel Janssen, Pathology.

12.00 - 12.30 Department of Cancer Genetics, Oslo University Hospital:

“DCIS and progression to invasive breast cancer-an update”, Therese Sørli

“Intra-tumor heterogeneity - examples from the NeoTax study”, Hege G Russnes

12.30 -13.30 Lunch

13.30 -14.00 Clinical group, Oslo University Hospital:

“Status for the EMIT study - PAM50/PAM50 ROR score results and implications in the Oslo1 and Oslo2 cohorts”, Bjørn Naume

14.00 - 15.00 “How to continue, a Regional Network for Breast Cancer Research”, Bjørn Naume and Kristine Sahlberg start discussion.

-